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Abstract  
Human neutrophil alpha defensins are antimicrobial peptides involved in the first line of defence against 
invading pathogens. To develop a deeper understanding of the immune responses in relation to airway 
inflammation and exercise induced epithelial damage it is necessary to have a sensitive method that can 
detect these peptides in a saliva matrix. A selective and sensitive Liquid Chromatography Mass 
Spectrometry (LC-MS) method for the detection of four salivary HNP (HNP1, HNP2, HNP3 and HNP4) 
peptides has been developed and validated. The LC-MS responses of HNPs 1-3 were compared with the 
response obtained from the traditionally used enzyme-linked immunosorbent assay (ELISA) that measures 
the combined levels of these three defensins. The peptides were separated on a Phenomenex Kinetex® C8 
column (50 x 3.0 mm, 2.6 µm) on an Agilent 1200 series HPLC system using a linear MeOH: H2O: acetic 
acid (0.1% v/v) gradient. The HPLC was coupled to a Waters Synapt G1 Electrospray Quadrupole Time 
of Flight mass spectrometer. A full scan range from 100-2000 m/z in the positive ion mode was used for 
the acquisition. The LC-MS method was linear for concentrations of HNP2 between 0.05 and 1 ng/µL 
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with a LOD of 0.05 ng/µL and LOQ of 0.1 ng/µL. Inter- and intra- assay precisions (%CV) were 0.3 and 
14.95%, respectively. HNPs were extracted from saliva by solid-phase extraction (SPE) with a recovery 
of 80-91%. The cross-validation data revealed no significance quantitative difference between LC-MS 
and ELISA (R2= 0.96) and confirms that the developed LC-MS method is a reliable method for the 
detection of these antimicrobial markers. However, superior selectivity in the developed LC-MS method 
provides a unique opportunity to assess individual alpha defensin levels in the same assay.  HNP1, HNP2, 
HNP3 and HNP4 were evaluated in young athletes before, and up to, 2.5 h after an exercise intervention 
in order to assess if the developed LC-MS method was sensitive enough to detect rapid changes in their 
relative levels.  
1.1 Introduction 
Human saliva is increasingly being used for proteomic and biomarker-discovery studies due to the ease 
of collection and simpler workflow compared with plasma and blood. Aside from a variety of electrolytes, 
enzymes and antibodies (immunoglobulins), saliva contains a diverse range of antimicrobial peptides 
(AMPs) and proteins. Similar to other mucosal surfaces, many of these AMPs form a constitutive barrier 
to invading pathogens entering the oral cavity [1]. Defensins are a family of highly cross-linked, 
structurally homologous antimicrobial peptides. They form part of the non-specific immune system that 
reacts against invading pathogens. Stored in neutrophils and released into the external environment by 
epithelial cells, they play an important role in early host defence against various types of infections [2-5]. 
Human α-defensins, one of three defensin subfamilies, consist of six members (Table 1) with four (HNPs 
1-4) identified in neutrophils [3,6-8]. HNP1, HNP2 and HNP3 have identical amino acid (aa) sequences 
with the exception of an additional amino acid in the N-terminus of HNP1 (alanine) and HNP3 (aspartate). 
HNP4 consists of 33 aa with 32% sequence homology to the other three defensins [3,6,8]. HNPs 1-4 have 
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three β-strands and two loops created by the disulphide bridges between highly conserved cysteine 
residues (2 and 4, 3 and 5). A third disulphide bridge exists between cysteine 1 and cysteine 6. Defensins 
compromise 30-50% of the protein content in human azurophil granules, corresponding to 5-7% of the 
total cellular protein content in the neutrophils [3]. The variation of HNPs is significant with 100 fold 
differences between subjects, and it is therefore difficult to define a normal range for individual 
antimicrobial peptides present in saliva [9-10]. These peptides are often present at high local 
concentration, often confined to specific cells in confined positions. They are then diluted in extracellular 
fluids presumably leading to some disagreement in their reported values. Gardner et al (2009) estimated 
that the saliva concentration in healthy individuals range between 1 – 10 µg mL-1 [21]. These levels 
increase in various systemic disease [11-25]. Levels of HNP4 are roughly 100 fold lower [26] than HNPs 
1-3.  
 
Defensins are effective microbicides against both Gram-positive and Gram-negative bacteria, fungi and 
viruses [2-5]. In addition, the peptides have been found to be overexpressed in various tumour cell lines 
[27-28]. Existing studies have suggested that the antimicrobial activity of AMPs, including defensins, is 
attributed to their ability to interact with a variety of molecular targets, present either on the cell surface 
(including membranes) or within cells. The mechanism of action depends on the electrostatic interactions 
between the cationic peptide characteristics of the defensins and the negatively charged phospholipid 
components in the microbial membranes [29-31].  
 
To date, plasma or serum levels of α-defensins have been quantified using ELISA [11-15], RIA [16], LC-
UV [17-19] and LC-MS [20-25]. Goebel (2000) quantified the levels of two defensin (HNP1 and HNP2) 
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in human saliva of healthy subjects by LC-ESI-MS using the extracted ion chromatogram (EIC) [20]. van 
den Broek (2010) validated a LC-ESI- MS method for the analysis of three α-defensins (HNPs 1-3) in 
plasma and serum [25]. Cabras (2010) analysed the salivary secretory peptidome profile in children 
affected by type 1 diabetes, and HNP1, HNP2 and HNP4 were semi-quantified using the EIC peak area 
[22]. To the authors’ knowledge, the only study to detect all four defensins (in conjunction with 58 other 
salivary proteins) was conducted by Peluso (2007) and measured HNPs 1-4 by LC-ESI-MS in ten healthy 
volunteers and in patients with Sjogren’s syndrome [24]. They found that HNP1 level in patients were 
higher than in the healthy controls. However, their method was not optimised for the detection of 
defensins, and as proline-rich proteins (PRPs) also were detected, the likelihood for HNP ion suppression 
is high. An optimised method for the detection of salivary HNPs will include removal of these highly 
abundant proteins by for example Solid Phase Extraction (SPE). Peluso and co-workers acidified saliva 
samples prior to analysis by LC-MS which will not remove interfering PRPs. 
 
HNP1-3 are traditionally measured in conjunction by ELISA due to structural similarities, making it 
impossible to discriminate between the three peptides. For this reason the role of HNPs 1-3, but not HNP4, 
are commonly investigated. Therefore, a reliable analytical method that detect classes of defensins (HNPs 
1-4) in a single assay will be a valuable aid in the diagnostic and prognostics of infectious diseases 
affecting the airways or the oral cavity. Mass spectrometry offers this opportunity. Numerous studies have 
suggested that exercise induces considerable physiological change in the immune system [32, 33] and 
provides a unique opportunity to evaluate the role of stress and immunological mechanisms [33]. 
Therefore, assessment of HNP levels during exercise could deepen our understanding of mucosal 
immunity and the effect of stress on this part of the immune response mechanism. Here, we present the 
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validation of an LC-ESI-MS method that allows simultaneous detection of four individual HNPs (HNP1, 
HNP2, HNP3 and HNP4) in human saliva. This validated method has provided an opportunity to assess 
individual HNP levels in athletes’ saliva, in order to understand their response to exercise. A cross-
correlation of the data with the commonly used ELISA (HNPs 1-3 assay) is also included.  
1.2 Experimental 
1.2.1 Chemicals and Reagents 
LC-MS grade water was obtained from Fisher Scientific (Dartford, UK), LC-MS grade methanol 
(Hipersolv Chromanorm) was obtained from VWR (Leicestershire, UK) and acetic acid (≥ 98% purity) 
from Sigma-Aldrich (Gillingham, UK). 
1.2.2 Instruments and LC-MS Experimental Conditions 
Saliva samples were analysed by LC-MS using an Agilent 1200 series HPLC from Agilent Technologies 
(Santa-Clara, USA) coupled to a Quadrupole Time of Flight Mass Spectrometer from Waters Synapt G1 
(Manchester, UK). The saliva was separated on a Kinetex® Core Shell C8 column (2.6 µm, 50 x 3.0 mm) 
(Phenomenex, USA). The mobile phase compositions were A: 0.1% (v/v) acetic acid in H2O and B: 0.1% 
(v/v) acetic acid in MeOH, and were delivered at a flow rate of 0.6 mL/min with a gradient of B 2-95% 
over a 45 minutes: In general, Eluent B was increased from 2 to 50% over 19 minutes, followed by an 
increase to 95% over 2 minutes. Eluent B was maintained at 95% for 3 minutes, followed by a rapid return 
to the initial condition of B (2%), which was maintained for 20 minutes for re-equilibration of the column. 
The injection volume was 10 µL. The mass spectrometer was equipped with ESI with the following 
settings: positive ionisation mode, capillary voltage 3.50 kV, sampling cone voltage 40.0 V, source 
temperature 150° C, desolvation temperature 500° C, cone gas flow 100 L/h, desolvation gas flow 1200 
L/h, and acquisition ranging from 100 to 2000 m/z. The identification of the salivary peptide was 
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confirmed using Uniprot. EICs were used for the analysis of salivary HNPs 1-4 and the change in HNP 
levels resulting from exercise (post 30 and 60 mins) were calculated from the EIC peak areas of HNPs 1-
3 ions corresponding to [M + 3H]3+, [M + 4H] 4+ and [M + 5H]5+. 
1.2.3 Sample Collection  
The human biological samples were sourced ethically and their research use was in accord with the terms 
of the informed consents. Participants refrained from drinking 10 minutes and eating 2 hours prior to 
producing a saliva sample. Unstimulated whole saliva was collected (spitting method) at a rate of no less 
than 1 mL/min. 1 g of saliva was transferred into a clean tube and stored at -80 ◦C until analysis. For the 
validation study, saliva from 1-11 participants were used.  
1.2.4 Exercise intervention 
Nineteen male and four female athletes (age: 23 ± 2.39 years; height: 1.7 ± 0.1 m; body weight: 76 ±11 kg) 
participated in the study. Participants were recruited from the sports science group at the University of 
Greenwich, Medway. Ethical approval was obtained from the University of Greenwich Ethics Committee. 
Each participant performed a circuit training workout-session. After a warm-up, the participants 
performed a total of three circuits involving one set of each following eight resistance exercises: 1) contra-
movement vertical jump 2) bench press; 3) parallel back squat; 4) upright row; 5) dumbbell alternate 
lunges; 6) shoulder press; 7) alternate lunges; 8) abdominal crunch. Every exercise included 12 repetitions 
using the maximum possible load (with exception of the abdominal crunch that involved 20 repetitions 
per sets). A minimum rest in between exercises equal to the time required to change from one exercise to 
the following was permitted. Recovery between circuits was 2-3 minutes. The session was completed in 
about 60 min. Salivary samples were collected before and post 30 and 60 mins after completion of the 
exercise (total intervention time 2.5 hours). Statistical analysis (Student’s T-test) was performed using 
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Microsoft Excel 2013. The data is presented as the mean (% increase) of HNPs 1-3 30 and 60 mins after 
exercise.  
1.2.5 Analysis of Defensins by LC-MS 
1mL of saliva was diluted with 1mL of 1% v/v aqueous acetic acid and centrifuged (12,000 g, 10 mins). 
Discovery® DSC-18 (500 mg, 3 mL) SPE cartridges from Supleco (Bellefonte, PA, USA) were used to 
clean up the saliva samples. SPE reduces the interference from salivary PRPs resulting in a cleaner mass 
spectrum compared to saliva treated by acidification only (method optimisation, data not shown). In 
acidified samples, PRP was found to co-elute and significantly interfere with the detection of HNP1 and 
HNP2 even in the EIC. The SPE cartridges were conditioned (15 mL of 50% v/v MeOH in 1% v/v aqueous 
acetic acid), followed by washing (5 mL of HPLC grade water) and equilibration (5 mL of 1% v/v aqueous 
acetic acid). The diluted saliva sample was loaded onto the cartridges at a flow rate of 1 mL min-1, the 
cartridges were washed (10 mL, HPLC grade water), and the peptides eluted (1 mL of 50% v/v MeOH in 
1% aqueous acetic acid). The eluents were dried in an integrated SpeedVac SPD 1010-130 (ThermoFisher, 
Colorado, USA). To account for losses, a quality control (QC), Leu-enkephalin (0.3 ng µL-1) was spiked 
into each saliva sample prior to SPE, and all levels were normalised according to the calculated SPE 
recovery.  
1.2.6 Analysis of Defensins by ELISA 
The saliva samples obtained from the 23 participants during weekly training sessions (pre, post 30 and 
post 60 mins of exercise) over a period of 2-6 weeks were used for the cross-validation study with LC-
MS data (total 210 samples). The saliva samples were centrifuged (12,000 g, 10 mins; 4°C) and the 
supernatant diluted (1000×) in the supplied sample dilution buffer. Each sample was analysed in duplicate 
with an ELISA kit (Hycult Biotech, Netherlands) according to the manufacturer’s instructions. A 
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calibration curve was constructed consisting of eight prepared standards; 0.15 to 10 ngmL-1 HNPs 1-3. 
Absorbance (450 nm) values were interpolated from the calibration standards using a four parameter 
logistic curve (My Assays, Version 2015). 
1.2.7 Method validation 
1.2.8 Linearity 
HNP2 standards (0.05, 0.1, 0.3, 0.6, 0.8 and 1 ng µL-1) were prepared in HPLC grade water and 
reconstituted with the mobile phase [(MeOH + H2O (50:50), both with 0.1% acetic acid v/v]. The 
standards were analysed with LC-MS in triplicates and the signal-to-noise ratio (S/N) was plotted against 
concentration. 
1.2.9 Precision  
Precision of the method for saliva samples was determined by analysis of samples with endogenous 
concentrations of the peptides and a QC (HNP2) samples spiked after SPE at three different concentrations 
(0.3 ng µL-1, 0.6 ng µL-1 and 0.8 ng µL-1) with samples analysed in triplicate (n=3). The samples were left 
at room temperature and re-analysed after 24 hours. Reproducibility was calculated from the EIC (peak 
area) and expressed as a coefficient of variation (%CV).   
1.2.10 Recovery 
Extraction recovery was determined by spiking HNP2 and Leu-enkephalin into saliva at three different 
concentrations (0.3 ng µL-1, 0.6 ng µL-1 and 0.8 ng µL-1). Both peptides were solubilised in MeOH: H2O 
(50:50). The endogenous concentrations of HNP1, HNP3 and HNP4 in these samples were also assessed 
and expressed as a %CV. The extraction recovery was determined by comparing the EIC peak area of the 
saliva sample spiked prior to SPE with saliva samples spiked post SPE, corrected for the peak area of the 
endogenous peptides.  
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1.2.11 Stability 
The stability of the HNP2 standard in saliva was investigated after one month of storage. A saliva samples 
were split into two, and HNP2 spiked into the samples at three different concentrations (0.3 ngµL-1, 0.6 
ngµL-1 and: 0.8 ngµL-1). The relative levels of HNP1, HNP3 and HNP4 were also assessed in these saliva 
samples. Following SPE, one of the sample were reconstituted in mobile phase and analysed by LC-MS 
(n=3), and one stored as a lyophilised powder for one month (-80◦C). The stability was calculated from 
EIC (peak area) and expressed as a %CV. The stability of the standard leu-enkaphalin in saliva was also 
assessed and compared with similar levels in a freshly prepared non-saliva matrix.  
1.3 Results and Discussion 
1.3.1 Separation and detection of HNPs   
The four salivary defensins (HNPs 1-4) were successfully separated and detected by LC-MS (Figure 1). 
Ions at RT 19.20 min with m/z 861 and 689 and 1147 (corresponding to [M+3H] 3+, [M+4H] 4+, [M+5H] 
5+) for HNP1, RT 19.49 min with m/z of 1124, 843 and 674 (corresponding to [M+3H] 3+, [M+4H] 4+, 
[M+5H] 5+ ) for HNP2, RT 19.56 min with m/z of 1162, 872 and 698 (corresponding to [M+3H] 3+, 
[M+4H] 4+, [M+5H] 5+ ) for HNP3, and RT of 20.74 min with m/z of 742 and 928 (corresponding to 
[M+3H] 3+, [M+4H] 4+ ) for HNP4 were the most intense ions in the mass spectra (Figure 2) . 
1.3.2 Method validation  
Linearity 
The HNP2 standard gave a linear response (EIC peak area vs concentration) in the range of 0.05 to 
1 ng µL-1 (R2 = 0.99). The mean determination (n=3) were 10 ± 6.7; 20 ± 0.1; 34 ± 0.1; 80 ± 1.6; 108 ± 
3.1; 140 ± 3.2 (0.05, 0.1, 0.3, 0.6, 0.8, 1 ngµL-1, respectively).  
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Precision 
The intraday %CV for endogenous HNP1, HNP3 and HNP4 (EIC peak area response) was in the range 
of 0.36-5% and the interday %CV was 6.4 -15% (Table 2). Interday precision was established from the 
re-analysis of the same sample after 24 hours. The intraday %CV of the EIC response of spiked HNP2 at 
three different concentrations (0.3 ng µL-1, 0.6 ng µL
-1 and 0.8 ng µL-1) was in the range of 0.6 - 3.1%, 
while the interday %CV of the response was 10.5-12.6%. Overall, the intraday %CV for HNP 1-4 (EIC 
peak area response) was in the range of 0-5% and the interday %CV was 6-15%. Likewise, the EIC peak 
area of spiked Leu-enkephalin into the saliva matrix was evaluated and the %CV determined to be 1% (24 
hours), which is within the acceptable range for repeatability (CV of <20%) [37-38]. Encouragingly, these 
values are similar to reported intra- and interday precisions for HNP1, HNP2 and HNP3 in plasma (9.8-
14.0%, 10-19%, LC-MS) and serum (5.6-6.7%, 7-10%, LC-MS) [25]. To avoid any bias, all athletes’ 
saliva samples were analysed immediately after SPE. 
Stability  
The stability of the endogenous peptides HNP1, HNP3, HNP4 and HNP2 spiked into the saliva matrix at 
three different concentrations was assessed up to twenty-four hours at room temperature (interday 
precision), and after one month in storage at -80°C (as a lyophilised powder following SPE) (Table 2). 
The peptides are considered stable when 85–115% of the initial concentration can be found. After twelve 
hours at room temperature, the %CV (peak area, PA) was in the range of 0.3 – 4.7% which increased to 
1.7 – 4.4% after twenty-four hours at room temperature. This indicates that the proteins are stable at RT 
for at least 24 hours. However, storage for one month at -80 °C resulted in an increase in the %CV range 
from 9.2 – 19.7 indicating that these peptides are not stable for longer period. It is well established that 
saliva should be stored at −80 °C rather than at −20 °C to slow down proteolytic activity within the sample 
[36]. The LC retention times did not shift significantly over the duration of 1 month (0.6-1.8 %CV). 
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The HNP2 standard was stable in solution for up to 5 hours, possibly due to the ability of the HNPs to 
form dimers and multimers [34]. van den Broek (2010) showed examples of ion suppression by the 
internal standard (HD5) and recommended use of isotope-labelled internal standards for the absolute 
quantification of individual HNPs [25]. Due to stability issues, Leu-enkaphalin was deemed a better choice 
of internal standard for quality control purposes and was spiked into saliva (0.3 ng µL-1) prior to SPE to 
correct for losses of analytes during sample preparation and to assess instrument sensitivity. 
Leu-enkephalin has become a commonly used reference material in MS. It typically produces one type of 
ion ([M + H]+ = 556.27 m/z) during ESI in the positive mode [35]. 
Recovery 
The recovery of the standards (HNP2 and Leu-enkephalin) was determined by comparing the EIC peak 
areas in the saliva matrix before and after SPE (Table 3). The standards were spiked into the saliva samples 
at three different concentrations (0.3 ng µL-1, 0.6 ng µL-1 and 0.8 ng µL-1). The recovery data revealed an 
acceptable recovery range of 83-92% for HNP2 and 89-93% for Leu-enkephalin.  
1.3.3 Correlation between LC-MS and ELISA data 
One of the objectives of this study was to compare the data obtained by LC-MS with that obtained by 
ELISA for the analysis of salivary HNPs. Due to the structural similarities between HNPs1-3, their 
combined levels are evaluated in standard ELISA. LC-MS data for these three analytes was therefore 
combined (mean % increase of HNP1-3 post 30 and 60 mins after exercise). Method validation parameters 
(linearity, precision and recovery) for the two methods are presented in Table 4. The data reveals that 
there is a good correlation (Figure 3) between the LC-MS and ELISA data for the measured levels of 
salivary HNP1-3 (n= 210; R2 = 0.96). Therefore, the developed LC-MS method can be considered an 
accurate analytical technique to measure individual HNPs 1-3 levels in saliva. It is worth noting that the 
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average LC-MS response (combined increases in HNP1-3 levels post resistance exercise intervention) 
tended to be higher, though not significantly, than the levels determined by ELISA (Figure 2), although 
this could be due to the fact that the saliva samples were stored at -80 ºC for longer between collection 
and analysis. Though ELISA provided a higher analyte recovery (90-101%) compared to the LC-MS 
method (80-91%) and a lower limit of detection (1.56 x 10-4 – 0.01 ngµL-1) compared to LC-MS (0.05 
ngµL-1), the developed method is highly selective at detecting four individual defensins and offers the 
potential to identify a plethora of other analytes in the same analytical run.  
1.3.4 Analysis of saliva samples from athletes 
To establish if the developed LC-MS method is sufficiently sensitive to detect individual HNPs 1-4 in 
male and female participants’ saliva samples a pilot study was conducted. In this study, HNP1 (EIC peak 
area) was the most abundant peptide compared to HNP2, HNP3 and HNP4. In addition, compared to the 
response of HNP1, the average HNP2 response was slightly, but not significantly, lower, whereas HNP3 
and HNP4 levels were similar (approximate 0.5 fold lower than HNP1). Goebel (2000) determined the 
levels of HNP1 and HNP2 in twenty healthy controls and reported ranges of 0.7-23 µgmL-1 and 0.5-17 
µgmL-1, respectively, and noted that in healthy controls the levels of HNP1 and HNP2 varies significantly 
[34]. Davison (2009) reported the concentration of salivary HNP1-3 was 0.1-0.5 ngmL-1, while in this 
study the concentration of HNPs 1-3 was in the range of 0.130-8.165 ng mL-1 determined by ELISA. After 
resistance training (post 60 mins), the levels increased significantly (p=0.016) ranging from 0.430 – 
13.449 ngmL-1 at 30 mins, and 0.686 – 40.590 ngmL-1 at 60 min post workout (p=0.013) (Table 5). The 
2.5h of resistant training resulted in extraordinary increases in the level of each individual HNP up to 
400% post 60 min exercise compared to the initial levels (Figure 4). The increase in HNP levels may result 
from compensation within the mucosal immune system and/or an exercise-induced airway inflammation 
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and epithelial damage, which may be a part of the normal stress response [21-23], however, further studies 
are needed to establish the underlying biological mechanism. It is yet to be determined if this increase in 
transient, though literature suggest so, and for how long the immune response is detectable. We are the 
first to show the individual responses of salivary HNPs (HNPs 1-4) induced by exercise. 
1.4 Conclusion 
An LC-MS method for the detection of four individual salivary human defensins has been developed and 
validated. The method meets the requirements of the ICH Q2B guidelines for the precision, linearity, and 
recovery for the analysis of individual HNPs in a saliva matrix [37-38]. A correlation was observed 
between the LC-MS and ELISA data for the analysis of salivary HNP1-3 and the developed LC-MS 
method can be considered an accurate analytical technique to measure individual HNPs 1-3 levels in 
saliva. In addition, the study confirmed that LC-MS can be used to determine the salivary levels of HNPs 
1-3 with adequate sensitivity, but higher specificity, as the traditional ELISA. The disadvantage of using 
immunoassay for salivary HNP1-3 measurement is that the kit is expensive, lengthy and does not 
discriminate between the HNPs 1-3. However, unlike the LC-MS data presented in this study, ELISA 
provides absolute amounts. To our knowledge, there is no report in the scientific literature of any 
investigation that has assessed the relative level of individual HNPs 1-4 by mass spectrometry in relation 
to exercise; after a high intensity circuit resistance training, salivary defensins levels were observed to 
increase significantly.  
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Table 1 Discovery (year, cell source and biological fluid), amino acid sequence and antimicrobial activity of human α-defensins (HNPs 1-6) 
adapted from reference [6].  
Year Name Sequence Length 
(AA) 
Mw* 
(Da)  
Cell sources Biological fluid Activity 
1985 HNP1 ACYCRIPACIAGERRYGTCIYQGRLWAFCC 30 3442.08 Neutrophils, monocytes, 
macrophages, natural killer 
cells, B cells and T cells 
Saliva, Plasma, Breast 
milk, BALF, Serum, 
Tears 
G, V, F 
1985 HNP2 CYCRIPACIAGERRYGTCIYQGRLWAFCC 29 3371.00 Neutrophils, monocytes, 
macrophages, natural killer 
cells, B cells and T cells 
Saliva, Plasma, Breast 
milk, BALF, Serum, 
Tears 
G, V, F 
1985 HNP3 DCYCRIPACIAGERRYGTCIYQGRLWAFCC 30 3486.09 Neutrophils, monocytes, 
macrophages, natural killer 
cells, B cells and T cells 
Saliva, Plasma, Breast 
milk, BALF, Serum, 
Tears 
G, V, F 
1989 HNP4 VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV 33 3709.45 Neutrophils Saliva, Plasma, Breast 
milk, BALF, Serum, 
Tears 
G, V, F 
1992 HD5 ATCYCRTGRCATRESLSGVCEISGRLYRLCCR 32 3582.18 Intestinal paneth cells and 
vaginal epithelial cells (HD5 
only) 
ND G, V, F  
1993 HD6 AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL 32 3708.27 Intestinal paneth cells ND V, F 
*Disulphide connectivity Cys2-Cys30, Cys4-Cys19, Cys9-Cys29 (HNP1, HNP3, HNP4), Cys1-Cys29, Cys3-Cys18, Cys8-Cys28 (HNP2), Cys3-Cys31, Cys5-
Cys20, Cys10-Cys30 (HD5), Cys4-Cys31, Cys6-Cys20, Cys10-Cys30 (HD6). G = Gram positive and Gram negative bacteria; V= viruses; F= fungi; AA = 
Amino acid. Peptide: HD = human α-defensin; HNP= human neutrophil peptide. Biological fluid: BALF= Bronchoalveolar lavage fluid; ND= not 
detected. 
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Defensins Concentration 
(ngµL-1) 
Intraday (12 hours) 
%CV 
Interday (24 hours) 
%CV 
Long term stability (-80◦C, one month)  
%CV 
  
HNP1 - 4.95 7.81 10.80 
 
- 1.22 9.39 11.36 
 
- 1.03 10.75 13.50 
HNP2 0.3 3.13 12.63 17.20 
 
0.6 0.64 10.62 13.90 
 
0.8 2.26 10.51 15.52 
HNP3 - 3.67 14.32 19.73 
 
- 2.38 14.36 15.23 
 
- 1.94 13.69 11.40 
HNP4 - 4.69 6.44 12.80 
 
- 3.00 10.54 12.70 
 
- 0.36 14.61 14.40 
Table 2 Intra-and interday precision, and stability data for HNPs 1-4 in human saliva. HNP2 were spiked into the saliva samples at three different concentrations (0.3, 0.6 
and 0.8 ng µL-1) post SPE and analysed by LC-MS (n = 3). The intermediate precision was calculated from the EIC (peak area) and expressed as a %CV. The endogenous 
relative levels of HNP1, HNP3 and HNP4 were also assessed in these samples. Samples were stored as a lyophilised powder (-80◦C) after SPE and reassessed after one 
month. 
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Table 3 Recovery of HNP2 and Leu-enkephalin. The standards were spiked into saliva samples at three concentrations (0.3, 0.6 and 0.8 ng µL-1) prior to and 
after SPE and analysed by LC-MS (n=5). The recovery was calculated from the EIC (peak area) and expressed as a %CV. 
 
 
 
 
 
 
Sample  Concentration (ngµL-1) EIC (mean count) ± 
SD  
%CV % Recovery 
Saliva - 33 ± 1.7  - 
HNP2 spiked prior to SPE 0.3 53 ± 1.6 5.15 -  
0.6 90 ± 0.5 3.02 -  
0.8 116 ± 2.6 0.56 - 
HNP2 spiked post SPE 0.3 58 ± 2.6 1.72 83  
0.6 101 ± 1.5 2.76 92  
0.8 124 ± 0.8 1.49 91 
     
Leu-enkephalin spiked prior to SPE 0.3 74 ± 4.2 0.65 - 
 0.6 111 ± 0.8 5.68 - 
 0.8 127 ± 0.7 0.72 - 
Leu-enkephalin spiked post SPE 0.3 82 ± 1.6 0.55 88 
 0.6 118 ± 0.2 1.95 94 
 0.8 136 ± 1.5 0.17 93 
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 Table 4 Method validation parameters for ELISA and LC-MS. 
 
 
 
 
 
 
 
 
 
 
 
 
Technique Peptide Linearity 
 
Precision (%) 
(Saliva Matrix)  
Recovery (%) 
(Saliva Matrix) 
ELISA  Averaged response from HNP1-3 HNP1-3 standard: 1.56x10-4 -0.01 ngµL-1 
(R
2 
= 0.99) 
Interday < 2% 
Intraday < 5% 
90-101% 
LC-MS Individual HNPs 1-3 HNP2 standard: 0.05-1 ngµL-1 
(R
2 
=
 
0.99) 
Interday 0-5% 
Intraday 11- 14.95% 
83-92% 
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Time interval HNP1-3 ngmL-1 (mean ±std) P value 
Pre 1.72 ± 2.20 - 
Post 30 3.20 ± 3.70 p = 0.01 
Post 60 6.80 ± 11.08 p = 0.01 
 
 
Table 5 Salivary HNP1-3 levels determined by ELISA (n=11).  
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Figure 1 Extracted ion chromatogram of salivary HNP1, HNP2, HNP3 and HNP4 obtained for ions 
corresponding to [M + 3H]
3+
, [M + 4H]
4+ 
and [M + 5H]
5+ 
 
Figure 2 ESI-MS spectra of salivary HNPs 1-4 obtained for ions corresponding to [M + 3H]3+, [M + 4H]4+ and [M + 
5H]5+.  
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Figure 3 Correlation between LC-ESI-MS and ELISA data (n= 210) The data is calculated as a mean (% increase) of 
HNP1-3 for post 30 and 60 minutes after exercise. The percentage increases were plotted against each other to 
assess the correlation between the two methods. 
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Figure 4 Percentages increases in salivary HNPs 60 mins post exercise. HNP1:415.9%, HNP2 396.7%, HNP3 
384.8%, and HNP4 185.8%. The peptides were detected by LC-ESI-MS after solid phase extraction. Error bars 
represent standard error (n=11). All increases are significantly higher compared to levels pre exercise.   
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